Grastek® is developed by Queen's University.

What development phase is Grastek® in?

Grastek® is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Grastek®

Queen's University · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Grastek®
Sponsor	Queen's University
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation (PHASE4)
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) (PHASE4)
Dose Finding Study Depigoid Phleum: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Grastek® CI brief — competitive landscape report
Grastek® updates RSS · CI watch RSS
Queen's University portfolio CI